Culley Brian M — SEC insider filings
SEC reporting owner CIK 1310683. 25 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2020-09-30 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 6 filings — 117,150 shares, $113,010 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 450,000 shares, $1,291,500 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 450,000 shares @ $2.87 ($1,291,500) in Lineage Cell Therapeutics, Inc., filed 2021-06-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | President and CEO, Director | 25 | 6 legs · 117,150 sh · $113,010 | 1 leg · 450,000 sh · $1,291,500 | 48 |
Insider filings — Culley Brian M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 40,500 @ $0.92 | EDGAR |
| 2026-03-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 15,000 @ $1.62 | EDGAR |
| 2026-03-06 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 3,250,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,250 · Tax withholding (F): 12,869 @ $1.80 · Option exercise (M): 31,250 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 8,925 · Tax withholding (F): 334 @ $1.68 | EDGAR |
| 2025-03-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 2,300,000 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,249 · Tax withholding (F): 12,547 @ $0.65 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 40,000 @ $0.60 | EDGAR |
| 2024-05-28 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 10,000 @ $1.05 | EDGAR |
| 2024-03-08 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,900,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,249 · Tax withholding (F): 12,806 @ $1.08 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
| 2023-03-10 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,900,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,249 · Tax withholding (F): 12,744 @ $1.35 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 · Tax withholding (F): 5,343 @ $1.58 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 · Tax withholding (F): 5,343 @ $1.54 · Purchase (P): 6,400 @ $1.53 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2022-03-28 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 5,250 @ $1.38 | EDGAR |
| 2022-03-11 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,250,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 124,997 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 · Tax withholding (F): 5,343 @ $2.45 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2021-10-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 · Tax withholding (F): 5,343 @ $2.52 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2021-06-30 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 300,000 @ $0.69 · Sale (S): 450,000 @ $2.87 · Option exercise (M): 15,450 @ $2.85 · Tax withholding (F): 5,343 @ $2.85 · Option exercise (M): 300,000 (derivative) @ $0 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 @ $2.35 · Tax withholding (F): 5,343 @ $2.35 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,165,100 (derivative) @ $0 | EDGAR |
| 2020-12-31 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 @ $1.76 · Tax withholding (F): 5,343 @ $1.76 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
| 2020-09-30 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 15,450 @ $0.94 · Tax withholding (F): 5,343 @ $0.94 · Option exercise (M): 15,450 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1310683 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs